Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Macular pigment optical density (MPOD) is not a molecule or receptor, but rather a quantitative measure of the concentration of specific dietary carotenoids—lutein, zeaxanthin, and meso-zeaxanthin—within the central retina (macula), especially in the fovea. These pigments act as internal "sunglasses," filtering out harmful blue light and providing antioxidant protection to photoreceptors. Higher MPOD is associated with better visual performance—including improved visual acuity, contrast sensitivity, glare recovery, reduced photophobia—and lower risk for age-related eye diseases such as age-related macular degeneration (AMD)[1][2][4]. The body cannot synthesize these carotenoids; they must be obtained from diet or supplementation. Measurement of MPOD serves as a non-invasive biomarker for assessing retinal defense mechanisms against oxidative stress but does not represent a therapeutic target like an enzyme or receptor would. Interventions focus on increasing dietary intake or supplementation with lutein and zeaxanthin to raise MPOD levels in at-risk individuals[1][2]. "Macular pigment is comprised of two dietary carotenoids, zeaxanthin and lutein... Healthy pigment functions like 'internal sunglasses', screening photoreceptors from oxidation and potential harm."[1] "The role of the [macular] pigment in the human eye is well described... It acts as an antioxidant by quenching reactive oxygen species and as a filter for damaging high energy/short-wavelengths of visible light (blue light)."[2] Because MPOD refers to a measurement/biomarker rather than an actionable molecular target, it should not be classified alongside receptors or enzymes. If you are seeking information about one of its constituent molecules—such as lutein or zeaxanthin—or about specific proteins involved in their transport/metabolism within the retina, those would be more appropriate molecular targets. Note: There is something incorrect about using "Macular pigment optical density" as if it were itself a druggable target; it describes a property measured clinically rather than any single molecule/protein/receptor amenable to direct pharmacological modulation.[7]
Dietary supplementation increases retinal carotenoid levels, raising MPOD and enhancing blue light filtration and antioxidant capacity
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Macular pigment optical density (MPOD).